#USA #New York #Citius Pharmaceuticals #LYMPHIR #Citius Oncology

Citius Pharmaceuticals to Present at Jefferies Global Healthcare Conference

Citius Pharmaceuticals, a prominent player in the biopharmaceutical arena, is making waves with its upcoming presentation at the Jefferies Global Healthcare Conference. Scheduled for June 5, 2025, at 3:10 PM ET in New York City, CEO Leonard Mazur is set to unveil the company’s latest advancements in oncology and critical care products. This conference marks a significant opportunity for Citius to engage directly with institutional investors and showcase its innovative therapies.

Event Details and Significance

The Jefferies Global Healthcare Conference is a highly anticipated event in the healthcare sector, bringing together industry leaders, investors, and analysts. Citius Pharmaceuticals has been recognized for its cutting-edge oncology subsidiary, Citius Oncology, which is at the forefront of developing targeted cancer treatments. Mr. Mazur's participation underscores the company's commitment to transparency and investor relations, allowing stakeholders to gain insights into ongoing developments and strategic direction.

The presentation will not only provide updates on Citius’s product pipeline but also illustrate the company’s vision for addressing critical healthcare needs. During the conference, attendees can expect discussions surrounding Citius’s flagship product, LYMPHIR, an innovative immunotherapy recently approved by the FDA for treating cutaneous T-cell lymphoma (CTCL).

A Look at LYMPHIR

LYMPHIR, which received its FDA approval in August 2024, is considered a groundbreaking treatment for patients with relapsed or refractory CTCL who have undergone prior systemic therapies. The estimated market demand for LYMPHIR exceeds $400 million, indicating a robust opportunity for Citius in the oncology space. The drug benefits not only from a unique mechanism of action but is also supported by extensive intellectual property protections, enhancing its competitive advantage in the market.

Other Noteworthy Products

In addition to LYMPHIR, Citius is advancing other products in its pipeline. Mino-Lok® is an antibiotic lock solution designed for salvage catheters in patients experiencing catheter-related bloodstream infections. Furthermore, the company is pioneering a topical formulation, CITI-002 (Halo-Lido), targeting hemorrhoid relief. Citius recently completed pivotal Phase 3 trials for Mino-Lok, achieving significant success in its endpoints, and is actively collaborating with the FDA on the next steps for its portfolio.

The presentation at the Jefferies Global Healthcare Conference is a pivotal moment for Citius Pharmaceuticals as it positions itself competitively within the biopharmaceutical landscape. With Mr. Mazur's expertise and leadership, stakeholders can anticipate a comprehensive overview of the company’s objectives and strategies moving forward.

Engaging with Investors

In addition to the formal presentation, Mr. Mazur will engage in one-on-one meetings with institutional investors during the conference. This will provide an exclusive platform for investors to inquire about specific aspects of the company’s operations and future directions. Investors are encouraged to coordinate their schedules through their Jefferies representatives, reflecting the company’s open approach to investor relations.

As Citius Pharmaceuticals continues to innovate and expand its product offerings, the Jefferies Global Healthcare Conference represents a significant milestone for the company, highlighting its commitment to advancing healthcare solutions and fostering partnerships within the investment community. For detailed information regarding the webcast and additional updates, attendees are advised to visit Citius’s official website. Overall, this event not only marks an opportunity for Citius to shine a light on its achievements but also reinforces its role as a key player in the healthcare sector.

For real-time updates and information, please check Citius Pharmaceuticals and Citius Oncology.